MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12020-023-03526-0

Медицинская библиотека · Endocrine · 2023

Cabozantinib for different endocrine tumours: killing two birds with one stone. A systematic review of the literature.

Zago Elena, Galluzzo Antonio, Pradella Silvia, Antonuzzo Lorenzo, Maggi Mario, Petrone Luisa, Sparano Clotilde

Систематический обзорКлинический случайСтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: Cabozantinib is an oral multi-tyrosine kinase inhibitor (TKI) that has been approved in Europe for advanced renal cell carcinoma, hepatocellular carcinoma, locally advanced and metastatic medullary thyroid carcinoma (MTC) and radioiodine-refractory differentiated thyroid cancer. Merkel cell carcinoma (MCC) is a rare and highly aggressive cutaneous malignant neuroendocrine tumour that usually presents in sun-exposed skin areas of immunosuppressed patients. Conflicting data exist about cabozantinib for MCC and this TKI is currently under investigation in several onco-endocrine frameworks.

METHODS

We herein report a case of an 83-year-old man who was diagnosed with MCC during the treatment of an advanced metastatic MTC. The diagnosis of MCC was established based on clinical, histopathologic evaluation and immunohistochemistry. A systematic review of the literature on cabozantinib use for advanced endocrine and neuroendocrine tumours has been performed.

RESULTS

The patient was initially treated with surgery and adjuvant radiotherapy. Cabozantinib was therefore started to control both MTC and MCC. After 24 months, no sign of local or metastatic MCC relapse was evidenced.

CONCLUSION

Promising data on cabozantinib treatment for endocrine and neuroendocrine neoplasms is recently emerging in the literature. In our clinical case, we reported that, besides the good response for the MTC, cabozantinib also seems to effectively control metastatic MCC, along with efficient surgery and adjuvant radiotherapy. Further investigations are needed to determine the efficacy and safety of cabozantinib in MCC patients and in off-label endocrine tumours.

Для цитирования: Zago Elena, Galluzzo Antonio, Pradella Silvia, Antonuzzo Lorenzo, Maggi Mario, Petrone Luisa, Sparano Clotilde. Cabozantinib for different endocrine tumours: killing two birds with one stone. A systematic review of the literature.. Endocrine. 2023. DOI: 10.1007/s12020-023-03526-0.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.